Abstract
Lipoprotein(a) levels are largely genetically determined and are linked to increased risk of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin followed by addition of tissue plasminogen activator. We then measured the time course of plasmin formation, determined as hydrolysis of H-D-valyl-l-leucyl-l-lysine-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r s=−0.46,P=0.002), and multiple regression analysis indicated that this relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Marcovina SM, Koschinsky ML. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997; 27:14.
Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary heart disease. Am J Cardiol 1998; 82:57U.
Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240.
Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue type plasminogen activator. In vitro studies in plasma milieu. Arterioscler Thromb Vasc Biol 1991; 11:629.
Leerink CB, Gimpel JA, Korlandt W, Bouma BN, Rijn HJ van. Kinetic analysis of lipoprotein(a) inhibition of plasminogen activation by tissue plasminogen activator in vitro. Fibrinolysis 1991; 5:233.
Hughes SD, Lou XJ, Verstuyft J, Grainger DJ, Lawn RM. Lipoprotein(a) vascular accumulation in mice. J Clin Invest 1997; 6:1493.
Angles-Cano E, Hervio L, Rouy D, Fournier C, Chapman JM, Laplaud M, Koschinsky ML. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrinbound tissue-type plasminogen activator. Chem Phys Lipids 1994; 67–68:369.
Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339:301.
Pekelharing HL, Kleinveld HE, Duif PF, Bouma BN, Rijn HJ van. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 1996; 75:497.
Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28:2370.
Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, Buller HR, ten-Cate JW. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997; 96:1612.
Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJ, Nesheim ME, Koschinsky ML. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin- modified fibrinogen surface. Biochemistry 1997; 36:10353.
Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem 1997; 272:11079.
Halvorsen S, Skyonsbert OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res 1992; 68:223.
Mao SJT, Tucci M, Tucci MI. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Lett 1990; 267:131.
Liu J, Harpel PC, Gurewich V. Fibrin bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 1994; 3:2554.
Declerk PJ. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1) Thromb Haemost 1993; 70:858.
Jauhiainen M, Metso J, Koskinen P, Ehnholm C. Characterization of the enzyme activity of human plasma lipoprotein(a) using synthetic peptide substrates. Biochem J 1991; 274:491.
Takada A, Urano T, Takada Y. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase. Thromb Haemost 1979; 42:901.
Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. The effect of the number of apolipoprotein(a) kringle 4 domains on the immunochemical measurement of lipoprotein(a). Clin Chem 1995; 41:246.
Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American Blacks and Whites. Biochem Biophys Res Commun 1993; 191:1192.
Marcovina SM, Hobbs HH, Albers JJ. Relationship between the number of apolipoprotein(a) kringle 4 repeats and mobility of the isoforms in agarose gel: bases for a standardized isoform nomenclature. Clin Chem 1996; 42:436.
Marcovina SM, Albers JJ, Wijsman E, Zhang Z-H, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res 1996; 37:2569.
Falcò C, Estellès A, Dalmau J, Españla F, Aznar J. Influence of lipoprotein(a) levels and isoforms on fibrinolytic activity — study in families with high lipoprotein(a) levels. Thromb Haemost 1998, 79:818.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Testa, R., Marcovina, S.M. The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 29, 128–132 (1999). https://doi.org/10.1007/s005990050077
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005990050077